- IHC-P
Unknown
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-LCAT antibody [EPR1384Y] (AB51060)
ab51060 (unpurified) at 1/100 dilution staining LCAT in paraffin embedded human brain tissue by Immunohistochemistry. Heat mediated antigen retrieval was performed before commencing with IHC staining protocol.
- IHC-P
Lab
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-LCAT antibody [EPR1384Y] (AB51060)
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) analysis of human liver tissue sections labeling LCAT with purified ab51060 at 1/100 dilution (1.03 μg/mL). Heat mediated antigen retrieval was performed using Bond™ Epitope Retrieval Solution 2 (pH 9.0) . Rabbit specific IHC polymer detection kit HRP/DAB (ab209101) was used as the secondary antibody. Negative control : PBS instead of the primary antibody. Hematoxylin was used as a counterstain.
The immunostaining was performed on a Leica Biosystems BOND® RX instrument.
- WB
Lab
Western blot - Anti-LCAT antibody [EPR1384Y] (AB51060)
In Western blot, Anti-GAPDH antibody [EPR16891] - Loading Control (ab181602) staining at 1/1000000 dilution.
Exposure time : Lane 1-3, 7-9 : 180 seconds; Lane 4-6 : 140 seconds
Low expression : HEK 293 (PMID : 7721870).
This blot was developed using a high sensitivity ECL substrate. The high-sensitivity ECL substrate used allows for the detection of proteins in the mid-femtogram range.
ab109417 is more sensitive than ab51060 in WB testing.
Lanes 1 - 6:
Western blot - Anti-LCAT antibody [EPR1384Y] (ab51060) at 1/1000 dilution
Lanes 7 - 9:
Western blot - Anti-LCAT antibody [EPR1383(2)] (<a href='/ko/products/primary-antibodies/lcat-antibody-epr13832-ab109417'>ab109417</a>) at 1/1000 dilution
Lanes 1, 4 and 7:
HepG2 (Human hepatocellular carcinoma epithelial cell) whole cell lysate at 20 µg
Lanes 2, 5 and 8:
COS-1 (Cercopithecus aethiops kidney epithelial) whole cell lysate at 20 µg
Lanes 3, 6 and 9:
HEK-293 (Human embryonic kidney epithelial cell) whole cell lysate at 20 µg
Secondary
All lanes:
Western blot - Goat Anti-Rabbit IgG H&L (HRP) (<a href='/ko/products/secondary-antibodies/goat-rabbit-igg-h-l-hrp-ab97051'>ab97051</a>) at 1/20000 dilution
Observed band size: 62 kDa
false
관련 conjugated 항체와 다양한 조성의 항체 (2)
-
Anti-LCAT antibody [EPR1384Y] - Low endotoxin, Azide free
-
Anti-LCAT antibody [EPR1384Y] - BSA and Azide free
Reactivity 정보
제품 세부 정보
Species reactivity
Mouse, Rat: We have preliminary internal testing data to indicate this antibody may not react with these species.
Please contact us for more information.
Patented technology
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free batch production
For more information, read more on recombinant antibodies.
특성 및 보관 정보
제형
Purification 테크닉
보관 버퍼
배송 시 보관 조건
적절한 단기 보관 기간
적절한 단기 보관 조건
적절한 장기 보관 조건
분주 정보
보관 정보
추가 정보
This supplementary information is collated from multiple sources and compiled automatically.
Biological function summary
This enzyme functions centrally in the maturation of high-density lipoprotein particles. LCAT interacts with and acts upon HDL converting nascent HDL into mature HDL by catalyzing the esterification of cholesterol. This process results in the sequestration of cholesterol within the core of HDL particles essential for reverse cholesterol transport to the liver. Moreover LCAT does not operate as part of a larger complex but is an active enzyme on its own within various lipid transport processes.
Pathways
LCAT's action significantly influences the lipid metabolism and reverse cholesterol transport pathways. In the lipid metabolism pathway it works closely with apolipoproteins such as apoA-I which serves as an activator. ApoA-I stabilizes the enzymatic action of LCAT promoting cholesterol homeostasis whereas LCAT ensures the efficient transfer of cholesterol to the liver within the reverse cholesterol transport pathway contributing to the maintenance of lipid balance.
제품 프로토콜
- Visit the General protocols
- Visit the Troubleshooting
타겟 정보
대체 명칭 보기
제품이 사용된 논문 (6)
Recent publications for all applications. Explore the 전체 목록 and refine your search
Journal of atherosclerosis and thrombosis 30:1070-1082 PubMed36384970
2022
Applications
Unspecified application
Species
Unspecified reactive species
Heliyon 8:e11271 PubMed36387451
2022
Applications
Unspecified application
Species
Unspecified reactive species
Yonsei medical journal 61:780-788 PubMed32882762
2020
Applications
Unspecified application
Species
Unspecified reactive species
Biomolecules 9: PubMed31779197
2019
Applications
Unspecified application
Species
Unspecified reactive species
Journal of lipid research 57:1059-73 PubMed27112635
2016
Applications
Unspecified application
Species
Unspecified reactive species
Reproduction (Cambridge, England) 139:163-76 PubMed19776099
2009
Applications
Unspecified application
Species
Unspecified reactive species
Product promise
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com